Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.

Autor: Anguille S; Antwerp University Hospital, Antwerp, Belgium.; Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium., Van de Velde AL; Antwerp University Hospital, Antwerp, Belgium.; Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium., Smits EL; Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium., Van Tendeloo VF; Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium., Juliusson G; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden., Cools N; Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium., Nijs G; Antwerp University Hospital, Antwerp, Belgium.; Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium., Stein B; Antwerp University Hospital, Antwerp, Belgium.; Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium., Lion E; Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium., Van Driessche A; Antwerp University Hospital, Antwerp, Belgium.; Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium., Vandenbosch I; Antwerp University Hospital, Antwerp, Belgium., Verlinden A; Antwerp University Hospital, Antwerp, Belgium.; Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium., Gadisseur AP; Antwerp University Hospital, Antwerp, Belgium.; Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium., Schroyens WA; Antwerp University Hospital, Antwerp, Belgium.; Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium., Muylle L; Antwerp University Hospital, Antwerp, Belgium.; Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium., Vermeulen K; Antwerp University Hospital, Antwerp, Belgium., Maes MB; Antwerp University Hospital, Antwerp, Belgium., Deiteren K; Antwerp University Hospital, Antwerp, Belgium., Malfait R; Antwerp University Hospital, Antwerp, Belgium., Gostick E; Department of Infection, Immunity and Biochemistry, Cardiff University School of Medicine, Cardiff, United Kingdom; and., Lammens M; Antwerp University Hospital, Antwerp, Belgium., Couttenye MM; Antwerp University Hospital, Antwerp, Belgium., Jorens P; Antwerp University Hospital, Antwerp, Belgium., Goossens H; Antwerp University Hospital, Antwerp, Belgium.; Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium., Price DA; Department of Infection, Immunity and Biochemistry, Cardiff University School of Medicine, Cardiff, United Kingdom; and., Ladell K; Department of Infection, Immunity and Biochemistry, Cardiff University School of Medicine, Cardiff, United Kingdom; and., Oka Y; Department of Respiratory Medicine, Allergy & Rheumatic Diseases., Fujiki F; Department of Cancer Immunology, and., Oji Y; Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan., Sugiyama H; Department of Cancer Immunology, and., Berneman ZN; Antwerp University Hospital, Antwerp, Belgium.; Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.

Publikováno v: Blood [Blood] 2017 Oct 12; Vol. 130 (15), pp. 1713-1721. Date of Electronic Publication: 2017 Aug 22.

Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia.

Autor: Verlinden A; Department of Haematology, Antwerp University Hospital, Edegem, Belgium., Jansens H, Goossens H, van de Velde AL, Schroyens WA, Berneman ZN, Gadisseur AP

Publikováno v: European journal of haematology [Eur J Haematol] 2014 Oct; Vol. 93 (4), pp. 302-8. Date of Electronic Publication: 2014 May 16.

Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.

Autor: Van Driessche A; Vaccine and Infectious Disease Institute (VIDI), Laboratory of Experimental Hematology, Faculty of Medicine, University of Antwerp, Antwerp, Belgium., Van de Velde AL, Nijs G, Braeckman T, Stein B, De Vries JM, Berneman ZN, Van Tendeloo VF

Publikováno v: Cytotherapy [Cytotherapy] 2009; Vol. 11 (5), pp. 653-68.

Acute myeloid leukaemia of mixed megakaryocytic and erythroid origin: a case report and review of the literature.

Autor: Daniëls L; Laboratory of Haematology, Antwerp University Hospital, Edegem, Belgium. danielslies@hotmail.com, Guerti K, Vermeulen K, De Raeve H, Van Assche E, Van de Velde AL, Berneman ZN, Van Der Planken M

Publikováno v: Acta clinica Belgica [Acta Clin Belg] 2007 Sep-Oct; Vol. 62 (5), pp. 308-14.

Primary non-Hodgkin's lymphoma in Bartholin's gland.

Autor: Tjalma WA; Division of Gynaecological Oncology, University Hospital Antwerp, Wilrijkstraat 10, 2650, Antwerp, Belgium. wiebren.tjalma@uza.be, Van de Velde AL, Schroyens WA

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2002 Dec; Vol. 87 (3), pp. 308-9.